Mind Medicine (MNMD) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
MindMed has appointed Gregg A. Pratt, Ph.D., as the Chief Regulatory and Quality Assurance Officer to enhance their regulatory capabilities and expedite progress in launching Phase 3 studies for treatments targeting anxiety and depressive disorders. This move aims to leverage Dr. Pratt’s expertise in securing approvals for groundbreaking psychiatric drugs, including a novel schizophrenia treatment.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
